BioSpace News Archive

TransCode Therapeutics, Inc., an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, announced that it has received notice from the NASDAQ Stock Market LLC that the Company has regained compliance with all applicable Nasdaq listing standards.

Surmodics, Inc. announced it has been awarded a group purchasing agreement for thrombectomy products with Premier, Inc. Effective June 1, 2024, the new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for Surmodics Pounce™ and Pounce™ Venous Thrombectomy Systems.

Kyowa Kirin, Inc., an affiliate of Kyowa Kirin Co., Ltd., a global specialty pharmaceutical company based in Japan, announced that its board of directors has approved plans to invest up to $530 million to build a new, state-of-the-art manufacturing facility in Sanford, North Carolina.

LENZ Therapeutics, Inc., a late clinical-stage biopharmaceutical company focused on developing the first aceclidine-based eye drop to improve near vision in people with presbyopia, announced that the Company will host a Key Opinion Leader event on Tuesday, June 18, 2024 at 8:00 a.m. ET.

Panbela Therapeutics, Inc., a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, announces an oral presentation at the Digestive Disease Week conference, which was held May 18-21, 2024.

Prime Therapeutics, LLC/Magellan Rx Management announces the appointment of health care leader Mike Edwards as president, markets.

Veru Inc. announced that the Company will present two presentations at the American Diabetes Association’s 84th Scientific Sessions, taking place June 21-24, 2024, in Orlando, Florida.

GeneDx, a leader in delivering improved health outcomes through genomic insights, announced that it is expanding access to its rapid whole genome sequencing services in neonatal intensive care units with leading health systems through a new collaboration with Epic.

BioSig Technologies, Inc. or, a medical technology company delivering unprecedented accuracy and precision to intra-cardiac signal visualization, announced the appointment of Mr. Ferdinand Groenewald to the position of interim Chief Financial Officer.